Skip to main content
MyPeptideDosagesMyPeptideDosages
blend12MG

AOD-9604 + CJC-1295 + Ipamorelin

12MG Protocol

AOD-9604 + CJC-1295 + Ipamorelin 12MG

Injection Freq.

Inject once daily

Cycle Sched.

8–12 weeks; optional extension to 16 weeks

Reconstitution

3.0 mL BAC water

Supports reduction in fat mass / enhanced lipolysis
May support lean‑mass gains via GH/IGF‑1 elevation
Selective GH release with minimal cortisol/prolactin effects
AOD‑9604 described as having placebo‑like safety in studies
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–1200 mcg AOD / 100 mcg CJC / 100 mcg Ip10
2Weeks 2–2300 mcg AOD / 150 mcg CJC / 150 mcg Ip15
3Weeks 3–12400 mcg AOD / 200 mcg CJC / 200 mcg Ip20

Inject once daily

8–12 weeks; optional extension to 16 weeks

This blend aims to pair a ‘GH‑fragment’ fat‑metabolism signal with two peptides that increase endogenous GH pulses. AOD‑9604 is described as a modified C‑terminal fragment of human growth hormone (aa 177–191) intended to retain lipolytic/anti‑lipogenic actions without meaningfully stimulating IGF‑1 or altering glucose metabolism. CJC‑1295 is presented as a longer‑acting GHRH analog that can sustain elevations in GH and IGF‑1, supporting anabolic and fat‑metabolism pathways over time. Ipamorelin adds a selective ghrelin‑mimetic pulse, designed to trigger GH release with minimal ACTH/cortisol activation. Together, the protocol frames the mechanism as complementary: AOD‑9604 provides a direct ‘fat‑loss’ style signal, while CJC + ipamorelin increase pulsatile GH output to mimic some of the body‑composition effects sought from exogenous GH—while still relying on endogenous release patterns. The protocol notes typical early‑cycle transient effects (flushing, headaches) and mild water retention as GH signaling rises.
Mild injection‑site redness/itching
Transient flushing or warmth
Headache
Lightheadedness (especially early)
Mild water retention with sustained GH elevation
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)

Related peptide protocols

More research-backed dosing guides in this category.